Series B financing to support ongoing Phase 1/2a clinical trial of Tegavivint in desmoid tumors and initiation of clinical trials in acute myeloid leukemia, non-small cell lung cancer and pediatric cancers HOUSTON, Feb. 16, 2021 /PRNewswire/ — Iterion Therapeutics, Inc. (“Iterion”), …